


GALVITA

GALENICS FOR LIFE





There is a large unmet medical need for children- and elderly-friendly formulations to reduce the administration burden for patients.



Therefore, Galvita has invented a patented technology platform with a novel material (TIP*) for age-appropriate formulations that feature fast oral disintegration, better taste masking and high drug load leading to better compliance as well as convenience, and in addition has major benefits for drug development

- in the formulation of new drugs (makes new APIs patient-ready and reduces time, risk and cost)
- and by repurposing generic products, extending patient populations and drug life cycles (additional patent protection**)



Performance of TIP is superior compared to currently available oral dosage forms such as direct-compression tablet technologies



Galvita is demonstrating the value of its proprietary platform with clinically developing its own products (for Proof-of-Concept and for marketing via partners)



The major sales potential will be realized by out-licensing TIP-technology to R&D-based and generics pharma companies, becoming a unique development partner



Galvita is realizing its potential with a highly experienced team, its own clinical development pipeline (currently 4 products), access to infrastructure (for pharmaceutical development, GMP-manufacturing, clinical applications / trials) and a scalable, global business model

* TIP = Template-Inverted Particles, patent pending | ** e.g. FDA guidance E11, PREA – pediatric research equity act, PIP – pediatric investigation plans

Galvita as Development Partner of Choice



Vision



Galvita is the **development partner of choice** for pharma companies, both innovators and generics, when it comes to solid dosage forms for children, elderly and problematic applications

Patients **benefit globally** from Galvita's technology and its set of capabilities




Mission



Galvita achieves **international reputation and success** with its unique combination of proprietary galenic technology, medical insight and market access

Galvita pursues **active partnerships** with pharma clients and complementary value providers



Galvita's business is based on a portfolio of **own products, value-adding services and licensed technologies**



Values



Team spirit comes first
Fairness and respect to all stakeholders



Driven by innovation and performance





Prof. Dr. Joerg Huwyler PhD

Co-Founder, Chairman
Head of Pharmaceutical
Technology Division
University of Basel



Dr. Maxim Puchkov PhD

Co-Founder, CTO
Researcher & Lecturer Dept.
Pharmaceutical Sciences,
University of Basel



Prof. Dr. Christoph R. Meier PhD, MA

Co-Founder
Head of Dept. of Pharm.
Sciences, Univ. of Basel,
Head Hospital Pharmacy
University Hospital Basel



Dr. Roland Haag PhD, MBA

Co-Founder, CEO
Head of Innovation Board at
University Hospital Zurich,
Startup Coach accredited at
Innosuisse



Prof. Dr. Marc Pfister MD FCP

Medical Advisor
Vice Chair Div. Paediatric
Pharmacology, Childrens
University Hospital Basel



Sascha Fritsche MA
HSG, CFA

Co-Founder, CFO
CFO Galvita, Entrepreneur in
Residence University
Hospital Zurich



Unmet Medical Need

Suitable Formulations for Problem Patients

Needs of pediatric, elderly and other problem patients:



Low drug adherence to swallow tablets / capsules: size, taste, etc.



Low **bioavailability** of the active substance (API) and insufficient speed of dissolution (rapid onset of action is key)

➤ Patient-friendly medicines improves compliance, quality of life, therapeutic outcome and cost effectiveness

Technology Challenges: Unsuitable Oral Formulations and Development

Technical challenges to develop new oral dosage forms with appropriate features to avoid



Technical risks: unsuitable formulations -> low patient acceptance




Time: formulation development of 6-12+ months is on the critical path for new drugs
(launch delay by one month can have a sales impact of CHF 100 million*)



Cost: cost of goods can become a success factor
(high cost of manufacturing for other sophisticated formulations)

➤ Technical and business challenges can be overcome with our
pharmaceutical technology



Galvita's first invention is a revolutionary technology with non-active ingredients: **TIP (Template-Inverted Particles)**

Our TIP technology features the following **pharmaceutical and clinical advantages**:



Ultra-rapid bioavailability due to a two-step disintegration mechanism



High drug load possible (up to 60%): allows for small tablets at usual dosages of active pharmaceutical ingredient (API) or high dosages without excessive tablet size



Water-free application (i.e. no water needed to swallow tablet)



Flexibility to tailor formulation characteristics to needs (disintegration speed, taste masking, etc.)



Broad applicability: usable for broad range of APIs and molecular weights, incl. APIs with low solubility



Low-cost manufacturing: no special equipment, standard materials



Natural anorganic material. Biodegradable. Biocompatible.




Targeted API release (oral cavity, pharynx, stomach)



Taste masking of API: high relevance for compliance of children



Hardness of tablet: easy to manufacture and apply, "perfect appearance"



Smart combination of experienced team, technological innovation, clinical proofs of concept and dual business model

Key factors why success will happen:



Experienced team: Unique combination of experience and expertise in pharma industry (Huwyler, Pfister, Haag), pharmaceutical technology (Huwyler, Meier, Puchkov), clinical pharmacology & trials (Pfister, Meier, Huwyler) and marketing / sales (Haag, Fritsche)



Technological Innovation: patent application for TIP, continued technology research for “TIP 2.0” (including e.g. personalization with data-based algorithms)



Clinical proofs of concept 2022: first clinical trials ongoing



Dual business model: application of Galvita technology for own products (including clinical development) and for licensing to pharma (formulation of new APIs, extending generic life cycles)

➤ Innovation brought to market with rapid scientific proof followed by a scalable business model